CTLA4 and cancer: With the widespread clinical application of the ‘first generation’ of immune checkpoint inhibitors (ICI), namely antibody-mediated blockade of cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein/ligand-1 (PD-[L]1), immunotherapy has become a mainstay approach for the treatment of cancer (1).